Abstract
Exposure to immunosuppressive medication in utero is an important cause of secondary T cell lymphopenia in infancy, which can be detected via T cell receptor excision circle (TREC) quantification on severe combined immunodeficiency (SCID) newborn screening (NBS). At present, there is a paucity of literature surrounding management of these infants. A protocol including recommendations for vaccinations and follow-up is needed to augment care. Patients referred to immunology for abnormal TREC results on NBS were identified as having in utero exposure to immunosuppressive medications and were followed until lymphopenia improved. The natural history of these patients’ lymphopenia was used to develop general management guidelines. Four infants with low TRECs secondary to in utero immunosuppressive exposure were evaluated. Medication exposures included azathioprine, infliximab, hydroxychloroquine, and fingolimod. All infants were born full term. TRECs ranged from 101–206 (normal value in IL ≥ 250 at time of testing, B-actin control). T cell lymphopenia (CD3 < 1500) was present in 50% of cases. Undetectably low effector CD4 naïve T cell population was present in 100% of cases. Mitogen proliferation was uniformly normal. Severity of TREC abnormality did not correlate with presence of T cell lymphopenia. Immune abnormalities normalized in 75% patients by age 4 months. All age-appropriate vaccinations, including live vaccines, were administered to all patients by age 4 months. It is critical to assess for in utero immunosuppressive exposure in infants with abnormal TREC results on NBS. In the infants evaluated, secondary T cell lymphopenia associated with maternal immunosuppressive use resolved or significantly improved by age 4 months. Once abnormal TREC count is deemed to be secondary to in utero immunosuppression and there are no other contraindications, infants may safely receive live vaccination, are able to drink breast milk, and do not require prophylactic anti-microbials.
References
Buchbinder D, Walter JE, Butte MJ, Chan WY, Chitty Lopez M, Dimitriades VR, Dorsey MJ, Nugent DJ, Puck JM, Singh J, Collins CA. When screening for severe combined immunodeficiency (SCID) with T cell receptor excision circles is not SCID: a case-based review. J Clin Immunol. 2021;41(2):294–302. https://doi.org/10.1007/s10875-020-00931-2.
Shazia L, Khan DA, Wysocki C. A late preterm infant with lymphopenia. Allergy and Asthma Proc. 2020;41(2):141–3.
Thomas C, Monteil-Ganiere C, Mirallié S, et al. A severe neonatal lymphopenia associated with administration of azathioprine to the mother in a context of Crohn’s disease. J Crohns Colitis. 2018;12(2):258–61.
Biggioggero M, et al. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus. 2007;16:651–6.
Smith RC, Patel NM, Sigmon R, Patel NC. Is rotavirus immunization safe in infants born to mothers treated with immunosuppressive drugs for inflammatory bowel disease during pregnancy? J Immunological Sci. 2020;4(4):41–4.
Author information
Authors and Affiliations
Contributions
Hallie Carol, Elisa Ochfeld, and Aisha Ahmed were involved in the research and have reviewed the manuscript. All authors have contributed to this work in a substantive and intellectual manner.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Disclaimer
This study was reviewed and determined to be exempt by the IRB of Ann & Robert H Lurie Children’s Hospital of Chicago.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Carol, H.A., Ochfeld, E.N. & Ahmed, A. In-utero exposure to immunosuppressive medications resulting in abnormal newborn screening for severe combined immunodeficiency: a case series on natural history and management. Immunol Res 70, 561–565 (2022). https://doi.org/10.1007/s12026-022-09297-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-022-09297-6